Immune delivery and activation in lymph nodes (LNs) provide boosted cancer nanovaccine efficacy, but tumor-induced immunosuppression in lymph nodes compromises nanovaccine efficacy. Toward that end, we engineered BIO-GEM, a hierarchically structured biomimetic lymph node (bLN) platform comprising genipin-crosslinked gelatin microspheres (GEM) encapsulating deformable albumin-hitchhiking nanoemulsions (BIO, generated with bovine albumin, imiquimod adjuvant, and OVA antigen). Compared to conventional microparticles used for immune cell recruitment, BIO-GEM forms antigen-rich depots that better recruit antigen-presenting cells (APCs) and T cells, creating an immunostimulatory niche for in situ T-cell priming. Collagenase-responsive degradation of GEM triggers sustained release of BIO, which targets LNs via the albumin-hitchhiking pathway. This spatiotemporal delivery strategy synergizes bLN-resident immune activation with LN-directed antigen trafficking, yielding high CD8+ T-cell infiltration at injection sites, dendritic cell maturation, and elicitation of antigen-specific cytotoxic T cells. In multiple B16 murine melanoma models, BIO-GEM significantly suppressed tumor growth and extended the survival of mice. Intradermal vaccination was more efficacious than subcutaneous or intramuscular injection routes.
Ren et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: